NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
National Cancer Institute (NCI)
Gilead Sciences
Gilead Sciences
West German Study Group
UNICANCER
Fundación GECP